A daily dose of a specific Vitamin E can improve liver disease, nonalcoholic steatohepatitis (NASH), a new study has revealed.
In addition, Actos (pioglitazone), a drug used to treat diabetes, also improved many features of NASH but was associated with weight gain.
NASH is a chronic liver disease that is linked to weight gain and obesity and can lead to cirrhosis, or scarring, liver cancer and death. It resembles alcoholic liver disease but occurs in patients who drink little or no alcohol. NASH can occur in children, the elderly, normal-weight, and non-diabetic persons.
The disease is apparently caused by abnormal metabolism of fats, which increases levels of oxidants, compounds that transfer oxygen in the liver.
In the Pioglitazone or Vitamin E for NASH Study (PIVENS), investigators from the NASH Clinical Research Network (CRN) compared the two different treatments to placebo.
Vitamin E functions as an anti-oxidant while Actos improves the sensitivity of cells to insulin, a hormone that controls sugar and fat metabolism.
PIVENS is the largest placebo-controlled, randomized clinical trial of therapies ever conducted for NASH.